{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T06:32:01Z","timestamp":1775111521367,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijid.2022.10.037","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T19:11:04Z","timestamp":1667243464000},"page":"233-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-7639","authenticated-orcid":false,"given":"Botond","family":"Lakatos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-1356","authenticated-orcid":false,"given":"B\u00e1lint Gergely","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2187-4666","authenticated-orcid":false,"given":"Ilona","family":"Bobek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9337-1841","authenticated-orcid":false,"given":"No\u00e9mi","family":"Kiss-Dala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2504-8188","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"G\u00e1sp\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Riczu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borisz","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal\u00e1zs Ferenc","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-7049","authenticated-orcid":false,"given":"L\u00e1szl\u00f3","family":"Gopcsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Bek\u0151","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-6828","authenticated-orcid":false,"given":"J\u00e1nos","family":"Sink\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Szl\u00e1vik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f3ra","family":"Mathi\u00e1sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"V\u00e1lyi-Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.10.037_bib0001","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin Definition","volume":"307","author":"Definition Task Force","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2022.10.037_bib0002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cmi.2021.11.007","article-title":"ESCMID COVID-19 living guidelines: drug treatment and clinical management","volume":"28","author":"Bartoletti","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.10.037_bib0003","unstructured":"Bobek I, Elek J, Gopcsa L, Lakatos B, Madurka I, Remenyi P, et\u00a0al. Igazolt COVID-19 fert\u0151z\u00f6tt feln\u0151ttek kezel\u00e9s\u00e9nek alapjai: Hungarian ministry of human resources, 2021."},{"key":"10.1016\/j.ijid.2022.10.037_bib0004","first-page":"121","article-title":"The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation","volume":"174","author":"Chatenoud","year":"1991","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.ijid.2022.10.037_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.10.037_bib0006","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12879-022-07192-x","article-title":"Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation","volume":"22","author":"De Bruyn","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2022.10.037_bib0007","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.10.037_bib0008","unstructured":"European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19), as of 3 December 2020. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/surveillance\/case-definition, 2020 (accessed 01 July 2022)."},{"key":"10.1016\/j.ijid.2022.10.037_bib0009","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study","volume":"27","author":"Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.10.037_bib0011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0013","first-page":"1","article-title":"Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort","volume":"9","author":"Karolyi","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2022.10.037_bib0014","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.10.037_bib0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3390\/medicina58040513","article-title":"Comparative efficacy of tocilizumab and baricitinib administration in COVID-19 treatment: a retrospective cohort study","volume":"58","author":"Kojima","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.ijid.2022.10.037_bib0016","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-Barrier): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.10.037_bib0018","unstructured":"National Directorate General for Hospitals. National E-Health Infrastructure. https:\/\/www.eeszt.gov.hu, 2022 (accessed 01 July 2022)."},{"key":"10.1016\/j.ijid.2022.10.037_bib0019","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"Osuchowski","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0021","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"Investigators","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0022","first-page":"e0702","article-title":"Tocilizumab versus baricitinib in patients hospitalized with COVID-19 pneumonia and hypoxemia: a multicenter retrospective cohort study","volume":"4","author":"Roddy","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.ijid.2022.10.037_bib0023","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.reuma.2020.10.009","article-title":"Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID-19: a real-world study","volume":"18","author":"Rosas","year":"2020","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ijid.2022.10.037_bib0024","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.10.037_bib0025","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.jinf.2020.09.010","article-title":"Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19","volume":"82","author":"Soriano","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ijid.2022.10.037_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697622","article-title":"The dynamic immunological parameter landscape in coronavirus disease 2019 patients with different outcomes","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2022.10.037_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.10.037_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","article-title":"International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2022.10.037_bib0029","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2022.10.037_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.866441","article-title":"Initiation of tocilizumab or baricitinib were associated with comparable clinical outcomes among patients hospitalized with COVID-19 and treated with dexamethasone","volume":"13","author":"Wong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijid.2022.10.037_bib0031","unstructured":"World Health Organization. Living guidance for clinical management of COVID-19. Geneva: World Health Organization, 2021. p. 1\u2013116."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122200577X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122200577X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:11:15Z","timestamp":1761120675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122200577X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":31,"alternative-id":["S120197122200577X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.10.037","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}